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Abstract
Objective
The potential of high-density lipoproteins (HDL) to facilitate cholesterol removal from arterial
foam cells is a key function of HDL. We studied whether cholesterol efflux to serum and
HDL subfractions is impaired in subjects with early coronary heart disease (CHD) or meta-
bolic syndrome (MetS) in families where a low HDL-cholesterol level (HDL-C) predisposes
to early CHD.
Methods
HDL subfractions were isolated from plasma by sequential ultracentrifugation. THP-1 mac-
rophages loaded with acetyl-LDL were used in the assay of cholesterol efflux to total HDL,
HDL2, HDL3 or serum.
Results
While cholesterol efflux to serum, total HDL and HDL3 was unchanged, the efflux to HDL2
was 14% lower in subjects with MetS than in subjects without MetS (p<0.001). The efflux to
HDL2 was associated with components of MetS such as plasma HDL-C (r = 0.76 in men
and r = 0.56 in women, p<0.001 for both). The efflux to HDL2 was reduced in men with early
CHD (p<0.01) only in conjunction with their low HDL-C. The phospholipid content of HDL2
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particles was a major correlate with the efflux to HDL2 (r = 0.70, p<0.001). A low ratio of
HDL2 to total HDL was associated with MetS (p<0.001).
Conclusion
Our results indicate that impaired efflux to HDL2 is a functional feature of the low HDL-C
state and MetS in families where these risk factors predispose to early CHD. The efflux to
HDL2 related to the phospholipid content of HDL2 particles but the phospholipid content did
not account for the impaired efflux in cardiometabolic disease, where a combination of low
level and poor quality of HDL2 was observed.
1. Introduction
A low HDL-cholesterol (HDL-C) level is a principal epidemiological risk factor for coronary
heart disease (CHD) [1]. Although recent Mendelian randomization studies [2,3] have shown
that the HDL-C level cannot be considered a causal factor for CHD, certain HDL subpopula-
tions may have a significant atheroprotective role. Plasma HDL consists of various particles
with distinct structures and atheroprotective properties [4]. The quantity [5] or quality of these
particles may be diversely changed in the low HDL-C level associated cardiometabolic disease
and this is not fully revealed by measuring total HDL-C level [6].
There are a number of studies linking cholesterol efflux with cardiometabolic disease. The
cholesterol efflux capacity to serum, rather than the macrophage-inherent efflux capacity, has
been reported to differ between subjects with low and high HDL-C levels [7]. CHD-patients re-
ceiving statin therapy with a normal LDL-cholesterol (LDL-C) level, a low HDL-C level and a
high triglycerides level exhibited a lower efflux capacity to serum and to total HDL than healthy
subjects [8]. The cholesterol efflux capacity to apoB-depleted serum associated inversely with
atherosclerosis and CHD independently of HDL-C or apoA-I levels [9]. Moreover, the risk of
future cardiovascular events was inversely associated with the cholesterol efflux capacity to apoB-
depleted plasma in a population-based cohort, even after adjusting for traditional cardiovascular
risk factors, HDL-C level and HDL particle concentration [10]. Nevertheless, it is still unclear
how the cholesterol efflux capacity to the HDL subfractions relates to cardiometabolic diseases.
Here we have studied the functionality of HDL subfractions in cardiometabolic disease.
The study samples were derived from Finnish families containing subjects with early CHD in
stable condition and a low HDL-C concentration prior to initiation of statin medication as
their major risk factor for the disease. The presence of the metabolic syndrome was also com-
mon in these families. Cholesterol efflux was measured from cholesterol-loaded THP-1 macro-
phages to total HDL, HDL2, HDL3 and serum. To provide greater insights into the efflux
parameters analyzed we assayed relevant biochemical and enzymatic factors of the HDL frac-
tions and the serum.
2. Subjects and methods
2.1 Study subjects
The study population (n = 112, Table 1) consisted of Northern Finnish families (n = 24) all of
which included a proband with early onset CHD and a low plasma HDL-C level. The inclusion
criteria for probands (not for other family members) were plasma HDL-C level below 1.0
mmol/L, LDL-C level below 4.0 mmol/L, triglyceride level below 3.0 mmol/L, no treatment
for diabetes and the first CHD event (acute myocardial infarction, coronary angioplasty or
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coronary bypass operation) before the age of 60. All the inclusion lipid criteria had to be ful-
filled in the probands before they started possible statin treatment. Altogether 42 subjects in
the entire study population were using statins by the time of blood sample collection and the
data in Table 2 is obtained from those blood samples. It is known that statin therapy elevates
the HDL-C level [11]. Subjects with a clinical manifestation of CHD, e.g. chest pain or dys-
pnea, but not fulfilling the previously mentioned criteria for CHD (see above) were defined as
unknown with respect to their CHD status (only 2 subjects in the families). Metabolic syn-
drome was defined based on IDF-criteria [12]. The subjects were collected between 2007 and
2009 in the Oulu University Hospital. A written informed consent was obtained from the sub-
jects. The study was approved by the Ethics Committee of the Oulu University Hospital.
2.2 Methods
2.2.1 Clinical measurements. Smoking history, alcohol intake and medications were
obtained from a questionnaire. The lifetime smoking burden was calculated as pack-years
(pack-year = 20 cigarettes smoked/day in one year) and alcohol intake was expressed as doses/
Table 1. Clinical characteristics of study subjects.
Men Women
All Early CHD a No CHD a MetS No MetS All MetS No MetS
N 58 30 20 33 25 54 25 29
Age (y) 51 (45–57) 52 (49–57) 52 (44–59) 53 (48–57)e 49 (32–53) 49 (37–65) 55 (43–67)d 45 (32–56)
CHD (n) 31 (53) 30 (100) 0 (0) 23 (70)f 8 (32) 8 (15) 6 (24) 2 (7)
Early CHD (n) 30 (52) 30 (100) 0 (0) 22 (67)f 8 (32) 5 (9) 4 (16) 1 (3)
CHD age (y) 47 (42–51) 47 (42–51) NA 48 (43–51) 46 (40–50) 57 (55–66) 57 (53–62) 63 (NA)
MetS (n) 33 (57) 22 (73) 10 (50) 33 (100) 0 (0) 25 (46) 25 (100) 0 (0)
Diabetes (n) 4 (7) 2 (7) 1 (5) 2 (6) 2 (8) 10 (19) 7 (28) 3 (10)
Hypertension (n) 16 (28) 14 (47)g 1 (5) 14 (42)g 2 (8) 22 (41) 17 (68)g 5 (17)
BMI (kg/m2) 28.2 (26.1–
30.0)
29.5 (27.5–
31.2)e
27.3 (25.1–
28.4)
29.3 (27.9–
30.7)e
26.3 (23.0–
28.2)
27.4 (24.1–
31.4)
29.8 (27.4–
33.5)e
24.8 (22.0–
27.5)
Waist (cm) 98 (91–104) 102 (97–107)e 95 (88–99) 103 (99–108)e 91 (84–95) 89 (81–98) 94 (88–104)e 82 (74–91)
Syst.BP (mmHg) 129 (118–
140)
130 (115–140) 130 (120–
141)
131 (122–141) 123 (114–
136)
126 (113–
142)
135 (118–143) 122 (111–
137)
ACE/ATII (n) 19 (33) 17 (57)g 1 (5) 15 (45)f 4 (16) 17 (31) 12 (48)f 5 (17)
Statin (n) 30 (52) 27 (90)g 1 (5) 20 (61) 10 (40) 12 (22) 9 (36) 3 (10)
Smoker (n) 20 (34) 10 (33) 5 (25) 12 (36) 8 (32) 9 (17) 5 (20) 4 (14)
Ex-smoker (n) 24 (41) 16 (53) 7 (35) 15 (45) 9 (36) 8 (15) 3 (12) 5 (17)
Pack-years b 12 (0–28) 23 (9–30)d 10 (0–15) 22 (10–32)e 5 (0–13) 0 (0–3) 0 (0–2) 0 (0–5)
Alcohol (dosesc/
week)
4 (1–8) 3 (0–6)d 5 (2–13) 4 (1–8) 4 (1–10) 1 (0–3) 1 (0–3) 1 (0–5)
Values are expressed as median (interquartile range) or as number of subjects (percentage). Abbreviations: CHD, coronary heart disease; CHD age, the
age of the first CHD manifestation; MetS, metabolic syndrome; ACE/ATII, angiotensin converting enzyme inhibitor or angiotensin receptor II blocker
medication; waist, waist circumference; syst.BP, systolic blood pressure; NA, not applicable.
a only subjects over 35 years of age included in age-matched groups
b 1 pack-year = 20 cigarettes/day during one year
c dose = 12 g of ethanol; Mann-Whitney U-test between early CHD / no CHD or between MetS / no MetS in sexes separately
d p<0.05
e p<0.01; Pearson chi-square test or Fisher’s test between early CHD / no CHD or between MetS / no MetS in sexes separately
f p<0.05
g p<0.01.
doi:10.1371/journal.pone.0171993.t001
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week (dose = 12 g of 100% alcohol). Waist circumference (cm), height (m) and weight (to the
nearest 100 grams) were measured and body mass index was calculated as weight / height
squared (kg/m2). Blood pressure was measured as a triplicate measurement on the brachium
with the Riva-Rocci method.
2.2.2 Blood samples. Blood samples were obtained after an overnight fast (minimum of
8 h). In patients with acute myocardial infarction or coronary bypass operation, the blood sam-
ples were taken at least 3 months after acute myocardial infarction or bypass operation. EDTA-
plasma and serum samples were obtained by centrifugation at 1500 x g for 15 min at +4C.
2.2.3 Clinical chemistry measurements. Serum insulin concentration and plasma glu-
cose, total cholesterol, LDL-C, HDL-C, triglycerides, free fatty acids and creatinine concentra-
tions and alanine transaminase activity were analyzed in the Laboratory of the Oulu University
Hospital. Insulin resistance was calculated as the Homeostatic Model Assessments (HOMA)
index i.e. (serum insulin [mU/L] x plasma glucose [mmol/L])/22.5 [13].
Table 2. Plasma/serum biochemical parameters of study subjects.
Men Women
All Early CHD a No CHD a MetS No MetS All MetS No MetS
N 58 30 20 33 25 54 25 29
Lipids and glucose
Total-C (mmol/L) 4.40 (3.88–
5.20)
3.95 (3.48–
4.40)d
5.20 (4.93–
5.98)
4.40 (3.90–
5.30)
4.30 (3.75–
5.00)
4.70 (4.10–
5.43)
4.70 (3.90–
5.80)
4.70 (4.20–
5.30)
HDL-C (mmol/L) 1.16 (1.00–
1.34)
1.07 (0.85–
1.17)d
1.28 (1.08–
1.67)
1.06 (0.88–
1.18)d
1.26 (1.17–
1.64)
1.50 (1.26–
1.69)
1.41 (1.13–
1.61)c
1.53 (1.35–
1.79)
LDL-C (mmol/L) 2.80 (2.28–
3.30)
2.40 (1.95–
2.90)d
3.30 (2.90–
4.00)
2.80 (2.30–
3.55)
2.80 (1.95–
3.15)
2.70 (2.38–
3.35)
2.70 (2.35–
3.55)
2.70 (2.35–
3.40)
TG (mmol/L) 1.32 (0.90–
2.13)
1.37 (0.97–
2.24)
1.38 (0.63–
2.14)
1.87 (1.16–
2.31)d
0.93 (0.59–
1.29)
1.03 (0.80–
1.38)
1.34 (1.07–
1.76)d
0.83 (0.64–
1.00)
FFA (mmol/L) 0.44 (0.34–
0.55)
0.41 (0.32–
0.54)
0.46 (0.35–
0.57)
0.44 (0.35–
0.55)
0.37 (0.33–
0.58)
0.57 (0.46–
0.74)
0.57 (0.44–
0.74)
0.57 (0.48–
0.74)
Glucose (mmol/L) 6.0 (5.5–6.6) 6.3 (5.7–6.7) 5.8 (5.5–6.4) 6.3 (5.8–6.7)d 5.5 (5.3–6.4) 5.6 (5.2–6.2) 5.9 (5.7–6.6)d 5.3 (5.1–5.6)
HOMA-index b 2.0 (1.3–3.4) 3.2 (2.0–4.5)d 1.5 (1.1–2.0) 2.9 (2.0–4.0)d 1.3 (0.8–2.0) 2.1 (1.3–3.9) 2.6 (1.8–4.7)d 1.4 (1.1–2.7)
Adiponectins
Total (mg/L) 5.99 (4.37–
8.92)
5.34 (3.94–
7.25)d
6.76 (4.85–
10.16)
5.46 (4.13–
6.42)d
7.60 (5.50–
10.33)
8.98 (7.27–
13.36)
8.23 (6.35–
11.94)
9.58 (7.63–
14.32)
HMW (mg/L) 1.65 (1.09–
3.20)
1.39 (1.08–
2.58)
1.91 (1.09–
3.98)
1.31 (1.09–
2.13)c
2.24 (1.22–
5.59)
3.11 (2.20–
5.29)
2.50 (1.62–
4.22)c
4.23 (2.39–
6.48)
Apolipoproteins
ApoA-I (g/L) 2.05 (1.79–
2.31)
1.95 (1.72–
2.18)d
2.22 (2.00–
2.49)
1.98 (1.78–
2.27)
2.09 (1.81–
2.48)
2.28 (1.95–
2.48)
2.29 (1.95–
2.50)
2.26 (1.95–
2.45)
ApoE in HDL
(mg/L)
1.93 (1.41–
2.77)
1.70 (1.32–
2.30)c
2.57 (1.51–
4.51)
1.68 (1.19–
2.18)d
2.50 (1.77–
4.40)
3.02 (1.16–
4.81)
1.75 (1.01–
3.77)
4.32 (1.31–
4.97)
Liver and kidney
ALT (U/L) 29 (21–36) 31 (25–41) 27 (20–34) 30 (22–40) 27 (18–33) 20 (15–29) 27 (17–33)d 17 (13–24)
Creatinine
(μmol/L)
70 (65–74) 69 (61–74) 72 (66–74) 69 (62–74) 70 (68–75) 61 (56–66) 59 (54–67) 61 (59–65)
Values are expressed as median (interquartile range). Abbreviations: Total-C, total cholesterol; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; TG,
triglycerides; FFA, free fatty acids; HMW, high-molecular weight.
a only subjects over 35 years of age included in age-matched groups
b see section 2.2.3 for details; Mann-Whitney U-test between early CHD / no CHD or between MetS / no MetS in sexes separately
c p<0.05
d p<0.01.
doi:10.1371/journal.pone.0171993.t002
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2.2.4 Adiponectin measurements. Total adiponectin and high-molecular weight (HMW)
adiponectin were measured using a Human adiponectin ELISA kit (Cat # EZHAPD-61K) and
a Human HMW-adiponectin ELISA kit (Cat # EZHMWA-64K) supplied by Linco Research
Inc. (Missouri, USA).
2.2.5 Isolation and analysis of chemical composition of lipoprotein fractions. Plasma
VLDL (d< 1.006 g/mL), LDL (1.019 < d< 1.063 g/mL), total HDL (1.063< d< 1.210 g/mL),
HDL2 (1.063 < d< 1.125 g/mL) and HDL3 (1.125 < d< 1.210 g/mL) were isolated by
sequential ultracentrifugation [14] using a Beckman ultracentrifuge (Ti 50.4 rotor, 259,000 x g
(49,000 rpm), +15˚C to isolate total HDL and Ti 50.2 rotor, 218,000 x g (49,000 rpm), +15˚C
to isolate HDL2 and HDL3). The isolated HDL fractions were immediately dialyzed against
PBS and stored at -70˚C (without any cryoprotective agent added) prior to the efflux experi-
ments. Isolated lipoprotein fractions were analyzed for lipids as described [15]. To obtain
actual plasma concentrations of the lipoprotein associated lipids the loss of lipoproteins in the
ultracentrifugation procedure was corrected as described [16].
2.2.6 Analysis of particle size of HDL subfractions. HDL particle size distribution was
analyzed by gradient gel electrophoresis as described [17,18]. Self-made 4–26% polyacrylamide
native gradient gels (8.0 X 8.0 cm) were used. The stained gels were scanned and analyzed as
described [19].
The HDL subfraction distribution was analyzed from the intensity curves using Gaussian
model fitting to ensure accurate and consistent subfraction quantifications [20]. The fitting
was performed using commercial curve-fitting software (www.perchsolutions.com) allowing
for a full optimization of the Gaussian lineshape for each individual intensity curve. The analy-
sis was able to distinguish between the two HDL subfractions, HDL2 and HDL3. The amount
of the subfractions was expressed as percentages of total HDL (the sum of both subfractions).
2.2.7 ApoA-I, apoE and preβ-HDL concentrations. Serum apoA-I concentration and
the concentration of apoE bound to spherical HDL fraction (measured from ultracentrifuged
total HDL fraction) were analyzed by ELISA [21]. Pre-beta-HDL was quantified by crossed
immunoelectrophoresis [22]. The pre-beta potential in Table A in S1 Table is defined as the
percentage of pre-beta HDL -associated apoA-I of serum total apoA-I after incubating serum
for 16 h at 37˚C temperature in the presence of LCAT inhibitor.
2.2.8 THP-1 cell culture. Human monocytic cell line THP-1 cells (ATCC #TIB-202,
Rockville, MD, USA; obtained from ATCC) [23] were grown on tissue culture treated, 96-well
flat-bottom plates with a lid (Costar, Corning Inc, Corning, NY, USA) in RPMI 1640 medium
(100 μl) supplemented with 2 mmol/L l-glutamine, 10 mmol/L HEPES, 1 mmol/L Na-pyru-
vate, 0.05 mmol/L β-mercaptoethanol, 4.5 g/L glucose, 100 U/mL penicillin, 0.1 mg/mL strep-
tomycin, and 10% FBS. The cells were further differentiated into mature macrophages by
exposure to phorbol 12-myristate 13-acetate (Sigma-Aldrich, St Louis, MO, USA). After 3
days, phorbol 12-myristate 13-acetate containing media were removed and the cells were
washed with PBS. FBS-free medium containing radioactive (3H-labelled cholesteryl-oleate)
acetylated LDL (50 ug/mL as LDL-protein, 2.0 μCi/mL) was added and incubated for 48
hours. Acetylated LDL was produced according to the method of Brown et al. [24]. The cell
cultures were maintained in humidified incubators at 37˚C in an atmosphere of 5% CO2.
2.2.9 Cholesterol efflux measurements. The method used in the cholesterol efflux experi-
ments has been previously described [19,25]. Efflux experiments were performed using 80% to
90% confluent cells in serum-free medium at 37˚C in a humidified atmosphere of 5% CO2 and
95% air. HDL samples of total HDL, HDL2, and HDL3 (50 μg/mL as protein) and serum sam-
ples (0.5% as volume) isolated from the study subjects were used as cholesterol acceptors. An
LCAT inhibitor (Na-iodoacetate, I9148 Sigma, 1 mmol/L final) was added to the serum sam-
ples used for efflux experiments immediately after their isolation to inhibit LCAT activity and
Cholesterol efflux and metabolic syndrome
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to maintain pre-beta HDL particles in the samples. Each plate also contained a zero sample of
plain medium and a control sample (isolated total HDL derived and pooled from several
donors in HDL-assays and a control serum sample in serum assay). The samples were incu-
bated for 18 hours after which medium was removed and filtered through a fritted 96 Deep-
wellTM plates (NUNC, Roskilde, Denmark). The cells were lysed overnight in 0.5 mol/L
NaOH. Aliquots of the medium and lysed cells were counted with a beta-counter (Wallac 1414
WinSpectralTM; Perkin Elmer, Wellesley, MA, USA) as a duplicate for radioactivity. Choles-
terol efflux was expressed as the percentage of radioactive cholesterol released into the medium
from total radioactive cholesterol present in the cells and in the medium per well. Efflux values
calculated as medium radioactivity divided by THP-1 cell protein content were correlated with
the values calculated as described above. Eight parallel wells were measured for every sample.
Individual (i.e. 1–2) outlier values were removed from these eight parallel values in (including
zero and control samples) 7 HDL2 samples, 8 HDL3 samples and 9 serum samples. After this,
a mean of the parallel values was calculated. In each plate, the mean of the zero sample was
subtracted from the mean of each sample, resulting in the final efflux value of a sample. Some
of the patient samples (all of them different subjects) were removed from efflux data as errone-
ous: 9 in HDL2 (3 men with CHD and MetS, 1 man with CHD only, 1 man with MetS only, 2
women with MetS, 2 healthy women); 3 healthy women in HDL3 and 1 man with MetS in
serum assay. The intra-assay coefficient of variation of the control samples was 6.9% for total
HDL, 3.3% for HDL2, 11.8% for HDL3 and 8.9% for serum assay. In the case of each acceptor
(total HDL, HDL2, HDL3, serum), every protocol step was performed during one day (i.e. in
one assay) for the entire study population and thus the inter-assay coefficient of variation
could not be calculated for single acceptors.
2.2.10 Statistical analysis. Generalized estimating equation model (GEE) [26,27] was used
to adjust statistical analyses for the fact that study subjects deriving from a same biological family
are biologically related to each other and thus non-independent observations. Pearson, Spear-
man and partial correlation analyses showed consistent findings compared with GEE models
and thus they were used to illustrate correlations. Student’s t-test, Mann-Whitney U-test, Pear-
son’s chi square test and Fisher’s test were used to show differences in baseline characteristics.
Skewed variables were log transformed to obtain the normal distribution for parametric meth-
ods. Statistical analysis was conducted with SPSS-software (IBM Corp. Released 2011. IBM SPSS
Statistics for Windows, Version 20.0. Armonk, NY, USA). To adjust for multiple testing, p<0.01
was considered statistically significant.
3. Results
3.1 Study population
The study population (112 subjects from 24 families) contained subjects with premature CHD
(30 men and 5 women). Twenty-six of the subjects with premature CHD had also MetS. In
addition, some family members without CHD had only MetS or a low HDL-C level. Clinical
and biochemical data of the study population are shown in Tables 1 and 2 which include sub-
jects both with and without statin medication. Serum HDL modulating protein parameters
and pre-beta HDL forming potential of the clinical groups compared in statistical analyses are
shown in Table A in S1 Table. CHD was not studied in females since the number of females
with early CHD was too low (Table 1) and the patients were clearly older than women without
CHD. Subjects with MetS were older than subjects without MetS (Table 1). Statin medication
was used mainly by CHD-affected subjects who also displayed heavier exposure to smoking
than subjects not affected by CHD (Table 1). Plasma/serum biochemical parameters were dif-
ferent between the clinical groups (Table 2).
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3.2 Cholesterol efflux from THP-1 macrophages
The cholesterol efflux data are shown in Table 3. Efflux to HDL2 was 14% higher (p<0.01) in
women than in men. No differences between sexes were found in the efflux to the other accep-
tors. Age was not significantly correlated with the efflux (Table F in S1 Table). No significant
correlations were found between the efflux parameters (Table B in S1 Table).
3.3 Composition of HDL fractions and their efflux capacity
To pursue more insight into the efflux capacity of the HDL fractions we analyzed the lipid and
protein composition of the fractions. The principal correlate with efflux to HDL2 was the ratio
of phospholipid content to total protein content in HDL2 particles (Table 4, r = 0.62 in men
Table 3. Cholesterol efflux and HDL2/HDL protein ratio in study subjects.
Men Women
All Early CHD a No CHD a MetS No MetS All MetS No MetS
N 58 b 30 b 20 b 33 b 25 b 54 b 25 b 29 b
Efflux to (%)
HDL 9.5 (1.5)c 9.6 (1.7) 9.5 (1.3) 9.6 (1.6) 9.4 (1.3) 9.8 (1.7) 10.1 (1.9) 9.6 (1.4)
HDL2 b 10.7 (2.3)d 9.8 (2.1)e 12.0 (2.3) 9.9 (2.1)g 11.7 (2.2) 12.2 (2.4) 11.4 (2.6)f 12.9 (2.0)
HDL3 b 14.4 (2.1)c 14.1 (2.7) 15.1 (0.9) 14.5 (2.3) 14.3 (2.0) 14.7 (1.8) 14.4 (2.2) 14.9 (1.3)
Serum b 13.6 (2.2)c 13.9 (2.4) 13.4 (1.9) 14.1 (2.3) 13.0 (2.1) 13.3 (1.9) 13.3 (2.2) 13.3 (1.7)
Ratio (%)
HDL2/HDL 17.8 (7.6)d 15.8 (6.3) 19.8 (8.8) 14.9 (6.1)g 21.7 (7.6) 22.7 (8.0) 19.6 (8.1)g 25.4 (6.9)
Values are expressed as mean (standard deviation). HDL2/HDL, a ratio of HDL2-protein to total HDL-protein.
a only subjects over 35 years of age included in age-matched groups
b missing efflux values: among men 5 HDL2 and 1 serum efflux (Early CHD 4 HDL2; No CHD 1 HDL2 and 1 Serum; MetS 4 HDL2 and 1 Serum; No MetS 1
HDL2) and among women 4 HDL2 and 3 HDL3 efflux (MetS 2 HDL2; No MetS 2 HDL2 and 3 HDL3); Student’s t-test men vs. women
c p>0.05
d p<0.01; When comparing clinical groups, P-values (p<0.01) of the B1-term are reported from two generalized estimating equation models (executed in
sexes separately): (1) efflux or HDL2/HDL = B1 x MetS + B2 x age + intercept, and (2) efflux or HDL2/HDL = B1 x early CHD + intercept
e p<0.01 vs. no CHD
f p<0.01 vs. no MetS
g p<0.001 vs. no MetS.
doi:10.1371/journal.pone.0171993.t003
Table 4. Partial correlation coefficients adjusted for age between cholesterol efflux to HDL, HDL2 and HDL3 and ratios of lipid or apolipoprotein E
content to protein content in a respective HDL fraction.
Efflux to
HDL HDL2 HDL3
Men Women Men Women Men Women
Total cholesterol/protein 0.21 0.40a -0.09 0.01 -0.01 0.11
Free cholesterol/protein 0.09 0.11 0.13 0.12 0.17 0.18
Esterified cholesterol/protein 0.24 0.46a -0.15 -0.04 -0.06 0.06
Triglycerides/protein 0.06 0.27 -0.58b -0.25 -0.16 -0.11
Phospholipids/protein 0.34a 0.36a 0.62b 0.77b 0.19 0.09
ApoE/protein -0.23 -0.19 - - - -
The apoE to protein ratio in HDL and all the composition measures in HDL2 are log-transformed.
a p<0.01
b p<0.001.
doi:10.1371/journal.pone.0171993.t004
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and r = 0.77 in women, p<0.001 for both). In HDL3 particles, the ratio of phospholipids to
total protein was not significantly correlated with their efflux capacity. These associations
remained essentially the same after statin using and CHD-affected subjects were removed
from the analysis or when confirmed by GEE-models (Tables C-D in S1 Table). In total HDL
particles, the ratio of phospholipid content to total protein content was correlated with their
efflux capacity in the whole study population (Table 4), but the associations were not signifi-
cant after excluding CHD-affected or statin using subjects (Tables C-D in S1 Table). Other
correlations were either inconsistent among sexes or relatively low.
When the HDL2 particle phospholipid per protein content was compared in respect to car-
diometabolic disease, it was reduced in men with MetS (p = 0.018, Table E in S1 Table) but no
other differences were seen.
3.4 Association of efflux to HDL2 with MetS and early CHD
Subjects with MetS displayed lower efflux to HDL2 than subjects without MetS (15% lower in
men and 12% lower in women, Table 3). The difference was significant after adjustment for
sex, age and the HDL2 particle phospholipid per protein content (p = 0.001, Table 5, Table G
in S1 Table) and remained similar but not significant after subjects on statin therapy or
affected by CHD were removed from the analysis (p = 0.014, Table H in S1 Table). In this sub-
group however, MetS was significantly associated with the efflux to HDL2 adjusted only for
sex and age, but not for the HDL2 phospholipid per protein content (p = 0.001, Table I in
S1 Table).
Since efflux to HDL2 was associated with MetS, its relationship to the parameters relating
to MetS was studied. The efflux to HDL2 was significantly and positively related to plasma
level of HDL-C and negatively with plasma level of VLDL-protein and waist circumference
adjusted for sex, age and the HDL2 phospholipid per protein content (Table 5, Table G in S1
Table). These relations remained significant after excluding the subjects receiving statin ther-
apy or affected by CHD (Table H in S1 Table). In addition the plasma levels of total triglycer-
ides and HOMA-index showed inverse associations with the efflux to HDL2 whereas the
Table 5. Cholesterol efflux to HDL2, early coronary heart disease (CHD) and metabolic syndrome.
Model Model predictors Beta P-value
Early coronary heart disease and metabolic syndrome 1a Early CHD (in men only) -2.19 <0.001
HDL2-phospholipids/proteinc 9.09 0.001
2b Metabolic syndrome -1.41 0.001
HDL2-phospholipids/proteinc 9.48 <0.001
Components of metabolic syndrome 3b HDL-cholesterold (mmol/L) 2.37 <0.001
HDL2-phospholipids/proteinc 6.86 0.003
4b Triglyceridesd (mmol/L) -0.83 0.042
HDL2-phospholipids/proteinc 9.12 <0.001
5b Waist circumference (cm) -0.06 <0.001
HDL2-phospholipids/proteinc 10.00 <0.001
Other metabolic parameters 6b VLDL-proteind (g/L) -8.55 0.002
HDL2-phospholipids/proteinc 8.15 <0.001
Generalized estimating equation model predicting efflux to HDL2
a adjusted for HDL2-phospholipids/protein, age-matched groups are compared in men only
b adjusted for HDL2-phospholipids/protein, age and sex; beta-coefficients denoted as ‘Beta’
c expressed as mmol/L of phospholipids per g/L of protein
d plasma concentrations.
doi:10.1371/journal.pone.0171993.t005
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plasma levels of total- and HMW-adiponectin displayed positive associations (Table 5, Tables
G-H in S1 Table). VLDL-particle concentration is inversely related to insulin sensitivity [28]
and the VLDL-protein level in Table 5 is reflecting VLDL-particle concentration.
The efflux to HDL2 was 18% lower in men with early CHD as compared with men without
CHD (Table 3). The difference was statistically significant adjusted for the HDL2 particle
phospholipid per protein content (p<0.001, Table 5). It became statistically non-significant
when adjusted for HDL-C level but remained significant when adjusted for other MetS param-
eters (Table I in S1 Table).
3.5 Serum HDL modulating protein parameters, serum potential to form
pre-beta HDL particles, clinical patient characteristics and cholesterol efflux
The HDL modulating protein parameters and the pre-beta HDL forming potential of serum
were measured to examine whether they affected the efflux to serum (or to HDL fractions),
and would this dissipate differences in the efflux parameters between the clinical groups. How-
ever, data from our analyses did not support this hypothesis (Tables A and F in S1 Table).
Alcohol intake was not associated with efflux (Table F in S1 Table), whereas smoking men
displayed significantly higher efflux to total HDL than non-smoking men (beta-coeffi-
cient = 1.01, p<0.01 for smoking status in generalized estimating equation estimating efflux to
total HDL with age and smoking status in men). Statins, angiotensin converting enzyme inhib-
itors and angiotensin receptor II blockers were used mainly by MetS- or CHD-affected sub-
jects and thus their independent effect on the efflux values could not be evaluated.
3.6 HDL subfraction distribution in MetS and early CHD
The HDL2/HDL protein ratio was significantly reduced in subjects with MetS in comparison
with subjects without MetS when adjusted for sex and age (p<0.001, 31% lower in men and
23% lower in women, Table 3, Table J in S1 Table). When comparing subjects with early CHD
and without CHD, this relative reduction of HDL2 in total HDL-protein did not reach statisti-
cal significance (Table 3, Table J in S1 Table). An exemplary image of a gel used to separate
HDL fractions in electrophoresis is shown in S1 Fig data supplement.
In summary, the HDL2 particle phospholipid per protein content was clearly positively associ-
ated with the cholesterol efflux capacity of HDL2 particles, but it did not account for the reduced
cholesterol efflux to HDL2 displayed by subjects with cardiometabolic disease in this family popu-
lation. No evident differences were detected in the other efflux parameters analyzed. In addition,
the subjects with MetS displayed a low HDL2/HDL protein ratio in their total HDL.
4. Discussion
This study shows an association between the cholesterol efflux to HDL2 and the MetS in a fam-
ily population, where the low HDL-C level and MetS predispose to early CHD. Supporting asso-
ciations between the efflux to HDL2 and the relevant metabolic parameters linked with MetS,
such as plasma HDL-C level, were detected. The ratio of phospholipids to total protein in the
HDL2 particles was the main structural correlate with their efflux capacity. The efflux to HDL2
was not independently associated with premature CHD in men when adjusted for HDL-C level,
though it was clearly lower in early CHD-affected men than in men without CHD.
To the best of our knowledge, the cholesterol efflux to HDL subfractions has not been stud-
ied in this kind of clinical setting. Tan et al. [29] reported that cholesterol efflux to both HDL2-
and HDL3 subfractions was low in subjects with acute coronary syndrome, whereas the CHD-
patients in our study were analyzed during their stable period. A similar finding as found in
our population was described in a study of obese women after weight loss induced by bariatric
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surgery [30]. The subjects in that study are metabolically comparable to the affected individu-
als examined here. The scavenger receptor BI (SR-BI)–mediated efflux to HDL2 was signifi-
cantly elevated at 6 months after surgery as compared with baseline, whereas the efflux
mediated by the ATP-binding cassette transporter G1 (ABCG1) remained unchanged. Efflux
to HDL3 displayed no significant change. These findings point to a functional link between
obesity and cholesterol efflux to HDL2.
In the present study, the HDL2 particle phospholipid per protein content was correlated
with the efflux capacity. The higher phospholipid to protein ratio in HDL particles has been
suggested to indicate larger lipoprotein particle size [31]. A relationship between phospholipid
content and efflux capacity of HDL particles has been detected both using hepatocytes and
macrophages [32–34]. More specifically, the phospholipid content and the size of the HDL
particles determine the cholesterol efflux mediated by the SR-BI [35–37]. Also ABCG1 medi-
ated efflux to HDL is correlated with the phospholipid content of HDL particles [38]. With
regard to our experimental model of acetyl-LDL loaded human THP-1 macrophages, the
ATP-binding cassette transporter A1 (ABCA1) pathway remains predominant, whereas
ABCG1 makes only a poor contribution to efflux, and cholesterol removal via the SR-BI path-
way is relatively more important [38,39]. Our efflux data are supported by the previous obser-
vation from Aron-Wisnewsky et al. [30], where SR-BI–mediated efflux to HDL2 was increased
by weight loss, but the question whether the impaired efflux to HDL2 observed in affected sub-
jects in this work was mainly SR-BI -mediated remains to be studied.
We used a well-established and widely utilized in vitro efflux assay [40–42] which measured
the efflux of labelled cholesterol from acetyl-LDL loaded THP-1 macrophages to isolated HDL
fractions or serum. In our efflux assay using serum as acceptor LCAT-activity was blocked to
maintain serum pre-beta HDL particle level. This treatment is different from what has been
used in most other whole serum efflux assays. It is noteworthy that the apoB-depleted serum
used in previous studies [9,10,43–45] contains enzymes and lipid transfer proteins capable of
modulating the metabolic pathways of HDL particles. Li et al. [43] showed that the majority of
the cholesterol measured in macrophage cell culture medium (containing apoB-depleted
patient serum) after the efflux assay did not reside within HDL particles. Thus, our method
using isolated HDL fractions or LCAT-inhibited whole serum as cholesterol acceptors is not
comparable to the apoB-depleted serum method.
There are certain limitations in the present study. The probands had per definition a low
HDL-C level prior to initiation of statin medication as a prominent risk factor for early CHD.
Thus, the CHD patients in this population may differ in this respect from CHD patients in the
general population. In addition, nearly all of the CHD-affected subjects were receiving statin
therapy. There are published reports that men with type 2 diabetes treated with simvastatin
and bezafibrate had increased cholesterol efflux to apoB-depleted plasma [46] and pitavastatin
treatment has been reported to increase cholesterol efflux to total HDL in dyslipidemic sub-
jects [47]. Accordingly, the statin users in our population might have displayed significantly
lower cholesterol efflux parameters prior to statin medication and this might have attenuated
the observed differences in the efflux parameters between the clinical groups. Finally, we did
not add any cryoprotective agent prior to freezing HDL samples and thus the lipoproteins may
have been modified by the freezing/thawing process. However, a study by Kekulawala et al.
[48] has shown that cholesterol efflux to HDL samples stored at -20˚C for 24 h was not signifi-
cantly impaired compared with a HDL sample stored at +4˚C. Another finding in the study
was that the freezing did not alter the size distribution of HDL particles in electrophoresis,
regardless of the usage of sucrose as a cryoprotective agent. Our storage temperature for the
samples was -70˚C.
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Only efflux to HDL2 fraction but not to other HDL fractions or serum was impaired in our
study. The subjects with MetS and low HDL-C level displayed a so-called ‘double-hit’, i.e. both
the low HDL2/HDL ratio and the impaired cholesterol efflux capacity to HDL2. The different
HDL2/HDL ratio could in part attenuate a difference in the cholesterol efflux to total HDL
fraction or to serum as the low HDL2/HDL ratio implies high HDL3/HDL ratio and the efflux
capacity of HDL3 fraction was not impaired. In previous studies, associations between choles-
terol efflux to serum and metabolic syndrome have been somewhat diverse, implying either
attenuated [7,8] or elevated [44,45] efflux capacity of serum in metabolic syndrome. These par-
adoxical associations could be partly explained by a high concentration of pre-β HDL particles
in serum with simultaneous high triglycerides level [45,49]. Importantly, a detailed experimen-
tal protocol and a cell model used for the efflux experiments affect the results observed. Despite
our negative result and these previous contradicting reports, sera from subjects with metabolic
dyslipidemia or metabolic syndrome may introduce cholesterol accumulation in macrophages
once the net cholesterol flux is estimated by measuring cholesterol influx in addition to efflux
[44]. At least two hypotheses for the specifically impaired efflux to HDL2 fraction can be con-
sidered. First, the HDL3 subfraction has been reported to be more resistant to oxidation than
the HDL2 subfraction [50] and thus HDL2 can be oxidized into a dysfunctional form impair-
ing its function in cholesterol efflux [51]. Alternatively, a modified phosphosphingolipidome
of HDL in cardiometabolic disease [52] could principally affect the cholesterol efflux to phos-
pholipid-rich HDL2 particles in our efflux assay.
There are at least two ways to interpret the pathological relevance of our findings. The
impaired efflux capacity of HDL2 fraction combined with unmodified efflux capacity to total
HDL fraction or to serum may have little clinical or biological relevance. On the other hand,
the impaired efflux to HDL2 alone could be relevant in vivo if there were, yet unknown, bio-
logical effects specific for macrophage cholesterol efflux to HDL2 particles of the cholesterol
acceptor spectrum. It is known that cholesterol efflux exerts various biological effects on many
cell types [53], and these outcomes are not always uniformly triggered by different apoA-I-
containing acceptor particle classes or efflux pathways. As an example, HDL specifically modu-
lates the activity of endothelial nitric oxide synthase by SR-BI-mediated cholesterol efflux
[54,55]. SR-BI has also been reported to mediate anti-inflammatory effects of HDL on macro-
phages although cholesterol efflux has not been shown to mediate these effects [56]. It might
turn out that specific lipidomic/proteomic profiling of HDL subclasses is needed to resolve in
more detail the particle associated factors affecting HDL–macrophage interaction and capacity
of cholesterol efflux.
5. Conclusion
The present work demonstrates that the low cholesterol efflux to HDL2 was a clear functional
feature of HDL in subjects with a low HDL-C level and derangement of metabolic state predis-
posing to early CHD. The ratio of phospholipids to total protein in HDL2 particles was posi-
tively associated with their cholesterol efflux capacity but the phospholipid content of these
particles did not account for the impaired efflux in cardiometabolic disease. In MetS, the
impaired efflux to HDL2 co-existed with the reduced protein ratio of HDL2 subfraction to
total HDL fraction. The clinical and mechanistic significance of this ‘double-hit’ remains to be
elucidated in future studies.
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